12 Jul Low Risk MDS
Posted at 16:26h
in
Author: Dr. Stefan D. Jevtic
Reviewer: Dr. Dina Khalaf
Objectives
At the end of the self-assessment module, participants will be able to:
- Describe an approach to the initial management approach of patients with lower-risk MDS
- Discuss the common adverse effects of erythroid-maturation agents in patients on this therapy for MDS
- Explain the initiation of erythroid-maturation agents and dose adjustments for patients experiencing adverse effects.
CHS Scientific Planning Committee Members (2021-22)
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology, Department of Oncology, McMaster University
Dr. Yan Xu – Fellow Physician, Hematology
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre
Conflicts of Interest: None